JP2016534996A - ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 - Google Patents

ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 Download PDF

Info

Publication number
JP2016534996A
JP2016534996A JP2016523209A JP2016523209A JP2016534996A JP 2016534996 A JP2016534996 A JP 2016534996A JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016534996 A JP2016534996 A JP 2016534996A
Authority
JP
Japan
Prior art keywords
patient
copd
antigen
binding fragment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016523209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534996A5 (enExample
Inventor
デア マーウェ，レネ ヴァン
デア マーウェ，レネ ヴァン
ワード，クリスティン
マーティン，ウバルド
ロスコス，ローリン
ワン，ビン
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2016534996A publication Critical patent/JP2016534996A/ja
Publication of JP2016534996A5 publication Critical patent/JP2016534996A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016523209A 2013-10-15 2014-10-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 Pending JP2016534996A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019132432A Division JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Publications (2)

Publication Number Publication Date
JP2016534996A true JP2016534996A (ja) 2016-11-10
JP2016534996A5 JP2016534996A5 (enExample) 2017-11-16

Family

ID=52809872

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016523209A Pending JP2016534996A (ja) 2013-10-15 2014-10-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2019132432A Active JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2021068065A Pending JP2021107421A (ja) 2013-10-15 2021-04-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019132432A Active JP6870037B2 (ja) 2013-10-15 2019-07-18 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
JP2021068065A Pending JP2021107421A (ja) 2013-10-15 2021-04-14 ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法

Country Status (12)

Country Link
US (4) US20150104447A1 (enExample)
EP (2) EP3057609A4 (enExample)
JP (3) JP2016534996A (enExample)
KR (1) KR20160061352A (enExample)
CN (2) CN113230399A (enExample)
AU (2) AU2014334563A1 (enExample)
BR (1) BR112016008082A2 (enExample)
CA (1) CA2925402A1 (enExample)
MX (2) MX2016004329A (enExample)
RU (1) RU2706729C2 (enExample)
SG (2) SG10201807318RA (enExample)
WO (1) WO2015057668A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532220A (ja) * 2019-05-16 2022-07-13 アストラゼネカ・アクチエボラーグ ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2992010B1 (en) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
BR112016014969A2 (pt) 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
JP6895884B2 (ja) 2015-06-01 2021-06-30 国立大学法人富山大学 肺高血圧症の治療薬及び治療方法
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
US20210230265A1 (en) * 2019-12-06 2021-07-29 Sanofi Biotechnology Methods for treating copd by administering an il-33 antagonist
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527356A (ja) * 2007-05-14 2010-08-12 メディミューン，エルエルシー 好酸球レベルを低下させる方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690474B2 (en) * 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
PT1176195E (pt) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
CN103328506A (zh) * 2010-10-15 2013-09-25 米迪缪尼有限公司 用于改善肺功能的疗法
EP2652498B1 (en) * 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
JP2014533246A (ja) * 2011-11-01 2014-12-11 メディミューン，エルエルシー 喘息の急性増悪の頻度および重症度を低下させる方法
LT3033101T (lt) * 2013-08-12 2019-03-25 Astrazeneca Ab Astmos paūmejimo dažnio sumažinimo būdai naudojant benralizumabą
HUE043497T2 (hu) * 2013-08-12 2019-08-28 Astrazeneca Ab Módszerek a kényszerített kilégzési térfogat növelésére asztmásoknál benralizumab használatával
TR201910413T4 (tr) * 2013-08-12 2019-08-21 Astrazeneca Ab Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527356A (ja) * 2007-05-14 2010-08-12 メディミューン，エルエルシー 好酸球レベルを低下させる方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIALS.GOV，'A STUDY TO EVALUATE THE EFFECTIVENESS OF A DRUG (MEDI-563) IN SUBJECTS WITH CH, JPN6018023791, August 2013 (2013-08-01), ISSN: 0003996838 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532220A (ja) * 2019-05-16 2022-07-13 アストラゼネカ・アクチエボラーグ ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
JP7657734B2 (ja) 2019-05-16 2025-04-07 アストラゼネカ・アクチエボラーグ ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法

Also Published As

Publication number Publication date
RU2706729C2 (ru) 2019-11-20
US20150104447A1 (en) 2015-04-16
RU2016118425A3 (enExample) 2018-07-19
EP3057609A1 (en) 2016-08-24
CN105636607A (zh) 2016-06-01
RU2016118425A (ru) 2017-11-21
EP3057609A4 (en) 2017-03-22
JP6870037B2 (ja) 2021-05-12
SG10201807318RA (en) 2018-09-27
US20200123262A1 (en) 2020-04-23
CA2925402A1 (en) 2015-04-23
MX2016004329A (es) 2016-11-10
JP2019203009A (ja) 2019-11-28
WO2015057668A1 (en) 2015-04-23
SG11201601807XA (en) 2016-04-28
MX2019013468A (es) 2020-02-12
EP3485902A1 (en) 2019-05-22
AU2020202333A1 (en) 2020-04-23
KR20160061352A (ko) 2016-05-31
US20170107291A1 (en) 2017-04-20
BR112016008082A2 (pt) 2017-10-17
AU2014334563A1 (en) 2016-04-07
US20180291108A1 (en) 2018-10-11
CN113230399A (zh) 2021-08-10
JP2021107421A (ja) 2021-07-29

Similar Documents

Publication Publication Date Title
JP6870037B2 (ja) ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
US10577414B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
HK40008332A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
HK1224583A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
US20210095037A1 (en) Methods for treating late-onset asthma using benralizumab
US20210380706A1 (en) Methods for treating severe asthma in patients with nasal polyposis
HK40118225A (zh) 使用贝那利珠单抗治疗增强型患者群体慢性阻塞性肺病的方法
Duncan Respiratory conditions
HK40090654A (zh) 右旋普拉克索用於治疗中度至重度哮喘的用途
Hardy Efficacy and safety of a budesonide/formoterol reliever therapy regimen in mild-moderate asthma: A randomised controlled trial

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190319